Eretz.bio
VC Fund
Brasil, Brazil
Eretz.bio is an initiative, started by Sociedade Beneficente Israelita Brasileira Albert Einstein, whose main mission is to foster entrepreneurship and innovation in healthcare in Brazil.For entrepreneurs and innovators, Eretz.bio is the ideal environment to develop their projects, supported by Einstein specialists and an extensive network ofBrazilian and international scientific leaders, executives and startup mentors.
- Total investments:
- 30
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Eretz.bio invests in
Stages Eretz.bio invests in
Countries Eretz.bio invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Danilo Gaspar
|
|||
Investment Focus
Industry
- Health Care 5 (17%)
- Medical 2 (7%)
- Oncology 2 (7%)
- Health Diagnostics 2 (7%)
- Eyewear 1 (3%)
Stage
- Seed 5 (17%)
- Pre-Seed 1 (3%)
Country
- Brazil 3 (10%)
- Chile 1 (3%)
- Argentina 1 (3%)
- United States 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Danilo Gaspar
Business Associate
|
Business Associate | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TELL Toolkit
|
TELL is on a mission to revolutionize the fight against neurodegenerative diseases like Alzheimer's, Parkinson's, and frontotemporal dementia. The company's innovative approach to brain health combines automated speech and language analysis with cutting-edge AI technology to detect early markers and provide reliable data to get todiagnoses.The company's HIPAA-compliant SaaS solution is designed to address the challenges of early detection, specificity, cost, access, and reliability. By offering a unified, user-friendly, and scalable tool for discovering and implementing novel markers, we're bringing hope to patients, caregivers, and healthcare professionals across the globe.So, whether you're a patient, physician, biotech company, health insurance provider, or government agency, TELL is here to help you make better decisions and improve brain health for all. | Pre-Seed / Jan 15, 2025 | |
Momentum Therapeutics
|
Momentum Therapeutics advances neurodegenerative disease treatments through innovative, aging-focused drug development. | Seed / Dec 16, 2024 | |
Korvitax
|
Korvitax develops minimally invasive devices to aid patients at risk of contrast-induced renal failure and other conditions. | Pre-Seed / Dec 06, 2024 | |
EYWA
|
EYWA designs the best processes and products to boost the adoption of psychedelic medicine, harnessing the power of biosynthesis. | $100K / Seed / Dec 05, 2024 | |
Dharma Bioscience
|
Dharma Bioscience is at the forefront of developing an innovative injectable treatment utilizing modified microRNAs to promote cartilage regeneration in patients with osteoarthritis. This advanced therapy offers a straightforward administration method for physicians worldwide, reducing the necessity for invasive joint replacement surgeries. Byproviding a non-invasive alternative, this injectable solution not only minimizes recovery time and associated costs but also presents patients with a safer and more accessible option for managing their condition. | Seed / Dec 04, 2024 | |
Kinzbio
|
Kinzbio use AI and genomics to develop phage-based solutions for health, environment, and food safety challenges. | Seed / Nov 05, 2024 | |
Scriba
|
Scriba uses AI to turn consultation audio into precise, real-time medical records, revolutionizing anamnesis. | Seed / Nov 05, 2024 | |
Echo Medical
|
Echo Medical optimizes surgical workflows with AI tools for consultations, material requests, and descriptions. | Venture - Series Unknown / Nov 05, 2024 | |
Fiibo
|
Fiibo is the first health and wellness multplatform in Brazil, offering an innovative technological solution that connects all healthcare stakeholders in one place. The platform includes an app that allows employees to choose from a variety of available products and services, as well as a data management and contracting platform for companies andbrokers. This provides greater freedom and flexibility in selecting how to care for one's health. | $250K / Seed / Jun 17, 2024 | |
Yeda Health
|
Yeda Health develops AI tools to analyze microbiota and biosensors, preventing glucose spikes and treating metabolic issues. | Pre-Seed / May 27, 2024 | |
| See all 30 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Eretz.bio invest in?
Eretz.bio invests primarily in Health Care, Medical and Oncology startups, most often at Seed and Pre-Seed stage. Most of the 30 investments tracked by Shizune back companies in Brazil. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Eretz.bio?
Public channels for Eretz.bio include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Eretz.bio?
The team at Eretz.bio includes Danilo Gaspar (Business Associate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
